Related Experiment Video

Updated: May 19, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Pathophysiological roles of endothelin receptors in cardiovascular diseases

Mamoru Ohkita1, Masashi Tawa, Kento Kitada

  • 1Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences, Japan.

Journal of Pharmacological Sciences
|August 7, 2012
PubMed

Insights

Endothelin-1 (ET-1) contributes to cardiovascular diseases (CVD) like hypertension. This review explores ET receptor roles, particularly ET(B), in CVD, highlighting its vasoprotective effects.

Area of Science:

  • Cardiovascular Biology
  • Endocrinology
  • Pharmacology

Background:

  • Endothelin-1 (ET-1), primarily from endothelial cells, significantly impacts cardiovascular regulation.
  • ET-1 is implicated in cardiovascular diseases (CVD) such as hypertension and atherosclerosis.
  • ET-1 exerts its effects through ET(A) and ET(B) receptor subtypes.

Purpose of the Study:

  • To review the current understanding of endothelin receptor roles in CVD.
  • To specifically focus on the function of the ET(B) receptor in cardiovascular pathophysiology.
  • To evaluate the therapeutic potential of ET receptor antagonism in CVD treatment.

Main Methods:

  • Literature review of existing studies on ET-1, its receptors, and CVD.
  • Analysis of physiological and pathophysiological roles of ET(A) and ET(B) receptors.
  • Examination of data from clinical and animal experiments regarding receptor antagonism.

Main Results:

  • Both ET(A) and ET(B) receptors on vascular smooth muscle cells mediate vasoconstriction.
  • ET(B) receptors on endothelial cells promote vasodilatation and ET-1 clearance.
  • The role of ET(B) receptor upregulation in nitric oxide system activation and vasoprotection is crucial.

Conclusions:

  • Selective or nonselective ET receptor antagonism is a potential CVD treatment strategy.
  • The vasoprotective effects mediated by ET(B) receptor activation require careful consideration for therapeutic approaches.
  • Further clarification is needed on the suitability of specific receptor antagonisms for CVD patients.

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...